Propranolol in conscious spontaneously hypertensive rats. II. Disposition after subcutaneous and intracerebroventricular administration
- PMID: 522894
- DOI: 10.1007/BF00498752
Propranolol in conscious spontaneously hypertensive rats. II. Disposition after subcutaneous and intracerebroventricular administration
Abstract
The disposition of dl-propranolol was studied in spontaneously hypertensive rats (SHR), both after subcutaneous (s.c.) and intracerebroventricular (i.c.v.) injection of 1 mg/kg. 1. Upon s.c. injection propranolol appeared rapidly in plasma. A maximum concentration of 374 +/- 33 ng/ml (N = 10) was reached 5 min after injection. After a distribution phase with a half-life of t 1/2 alpha = 17 min propranolol was eliminated with a t 1/2 beta = 59 min. 2. Both propranolol and its metabolites were taken up rapidly into all tissues studied. Highest concentrations (10.4 +/- 1.5 micrograms/g, N = 5) were found in lungs 30 min after injection. 3. Neither propranolol nor its metabolites accumulated in any of the tissues examined. 4. Upon i.c.v. injection of propranolol, a maximal concentration of 573 +/- 47 ng/ml (N = 3) was reached in plasma already 2 min after injection. In this case t 1/2 alpha was 13 min and t 1/2 beta was 80 min. 5. Dialysis experiments indicated that propranolol is bound to plasma proteins for 92% in the concentration range of 20--100 ng/ml. With increasing concentrations binding diminishes progressively. At the highest concentration tested (345 ng/ml) only 76% was bound. It is concluded that s.c. and i.c.v. injection of an identical dose of propranolol gives a similar plasma concentration-time profile. Moreover, it is suggested that the pharmacokinetic behaviour of propranolol in SHR does not explain the delayed antihypertensive effect of this drug.
Similar articles
-
Steady-state disposition of propranolol and its total metabolites in the spontaneously hypertensive rat: chronic subcutaneous vs. intracerebroventricular infusion with osmotic minipumps.J Pharmacol Exp Ther. 1979 Jun;209(3):317-22. J Pharmacol Exp Ther. 1979. PMID: 439006
-
Propranolol in conscious spontaneously hypertensive rats. I. Cardiovascular effects after subcutaneous and intracerebroventricular administration.Naunyn Schmiedebergs Arch Pharmacol. 1979 Oct;309(1):13-8. doi: 10.1007/BF00498751. Naunyn Schmiedebergs Arch Pharmacol. 1979. PMID: 522893 No abstract available.
-
Lack of a centrally-mediated antihypertensive effect following acute or chronic central treatment with AT1-receptor antagonists in spontaneously hypertensive rats.Br J Pharmacol. 1995 Dec;116(8):3181-90. doi: 10.1111/j.1476-5381.1995.tb15122.x. Br J Pharmacol. 1995. PMID: 8719794 Free PMC article.
-
Pharmacokinetics of propranolol: a review.Postgrad Med J. 1976;52 Suppl 4:22-25. Postgrad Med J. 1976. PMID: 787953 Review.
-
Clinical pharmacokinetics of propranolol.Clin Pharmacokinet. 1979 Mar-Apr;4(2):73-90. doi: 10.2165/00003088-197904020-00001. Clin Pharmacokinet. 1979. PMID: 378502 Review.
Cited by
-
Avoidance of "first-pass" elimination of rectally administered propranolol in relation to the site of absorption in rats.Pharm Res. 1984 Jul;1(4):164-8. doi: 10.1023/A:1016396508058. Pharm Res. 1984. PMID: 24277285
-
Changes in neurotransmitter sensitivity in the mouse neocortical slice following propranolol and theophylline administration.Br J Pharmacol. 1991 Mar;102(3):711-7. doi: 10.1111/j.1476-5381.1991.tb12238.x. Br J Pharmacol. 1991. PMID: 1364843 Free PMC article.
-
Methionine Restriction Partly Recapitulates the Sympathetically Mediated Enhanced Energy Expenditure Induced by Total Amino Acid Restriction in Rats.Nutrients. 2019 Mar 26;11(3):707. doi: 10.3390/nu11030707. Nutrients. 2019. PMID: 30917593 Free PMC article.
-
The pharmacokinetic properties of yohimbine in the conscious rat.Naunyn Schmiedebergs Arch Pharmacol. 1988 May;337(5):583-7. doi: 10.1007/BF00182736. Naunyn Schmiedebergs Arch Pharmacol. 1988. PMID: 3412496
-
Brain levels and acute antihypertensive activity of beta-blockers.Eur J Clin Pharmacol. 1985;28 Suppl:13-9. doi: 10.1007/BF00543704. Eur J Clin Pharmacol. 1985. PMID: 2865143